Giant Cell Arteritis – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of giant cell arteritis (GCA) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of GCA for each country, as well as annualized case counts projected to the national population.

All patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets covered in this report.

Clarivate Epidemiology’s GCA forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of GCA over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of diagnosed incident cases for each forecast year, Clarivate Epidemiology provides 20 years of forecast data for the following GCA subpopulations:

  • Diagnosed prevalent cases.​​​​​​
  • Diagnosed incident cases with PMR.

Note: Coverage may vary by country.